A phase I clinical trial to evaluate the safety, tolerance and pharmacokinetics of BA1105 in patients with advanced solid tumors
Latest Information Update: 28 Jan 2022
At a glance
- Drugs BA 1105 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Luye Pharma Group
- 26 Jan 2022 According to a Luye Pharma Group media release, first patient has been enrolled in this trial.
- 26 Jan 2022 Status changed from planning to recruiting, according to a Luye Pharma Group media release.
- 11 Oct 2021 New trial record